Evaluating Positron Emission Tomography in Non-small cell Lung Cancer: Moving Beyond Accuracy to Outcome

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer ImagingLung and Breast Carcinomas

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/B978-012374212-4.50029-8
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Bmc Medical Research Methodology Open Access Intra-cluster Correlation Coefficients in Adults with Diabetes in Primary Care Practices: the Vermont Diabetes Information System Field Survey

  2006cited by this paper
• How to use an Article on Economic Analysis of Clinical Practice

  2005cited by this paper
• FDG-PET in addition to conventional work-up in non-small-cell lung cancer.

  2005cited by this paper
• Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.

  2004cited by this paper
• Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer.

  2004cited by this paper
• Clinical decisions associated with positron emission tomography in a prospective cohort of patients with suspected or known cancer at one United States center.

  2004cited by this paper
• Traditional versus up-front 18FDG PET staging of non-small cell lung cancer (NSCLC): A Dutch Co-operative randomized study.

  2004cited by this paper
• The noninvasive staging of non-small cell lung cancer: the guidelines.

  2003cited by this paper
• Prospective use of serial questionnaires to evaluate the therapeutic efficacy of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in suspected lung cancer

  2003cited by this paper
• How morphometric analysis of metastatic load predicts the (un)usefulness of PET scanning: the case of lymph node staging in melanoma

  2003cited by this paper
• Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative

  2003cited by this paper
• The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment.

  2003cited by this paper
• Noninvasive staging of non-small cell lung cancer: a review of the current evidence.

  2003cited by this paper
• Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study

  2003cited by this paper
• Cost-Effectiveness of Alternative Management Strategies for Patients with Solitary Pulmonary Nodules

  2003cited by this paper
• Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.

  2003cited by this paper
• Test Performance of Positron Emission Tomography and Computed Tomography for Mediastinal Staging in Patients with NonSmall-Cell Lung Cancer

  2003cited by this paper
• Practice, efficacy and cost of staging suspected non-small cell lung cancer: a retrospective study in two Dutch hospitals

  2002cited by this paper
• Study design for concurrent development, assessment, and implementation of new diagnostic imaging technology.

  2002cited by this paper
• STAGING OF NON–SMALL-CELL LUNG CANCER AND APPLICATION OF FDG-PET

  2002cited by this paper
• Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial.

  2002cited by this paper
• FDG–PET sensitivity for melanoma lymph node metastases is dependent on tumor volume

  2001cited by this paper
• Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis.

  2001cited by this paper
• Re: Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.

  2001cited by this paper
• Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.

  2001cited by this paper
• PET scans and technology assessment: déjà vu?

  2001cited by this paper
• Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.

  2001cited by this paper
• Preoperative staging of non-small-cell lung cancer with positron-emission tomography.

  2000cited by this paper
• Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy.

  1999cited by this paper
• The role of randomization in clinical studies: myths and beliefs.

  1999cited by this paper
• Primary staging and follow‐up of high risk melanoma patients with whole‐body 18F‐fluorodeoxyglucose positron emission tomography

  1998cited by this paper
• Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-Based Medicine Working Group.

  1997cited by this paper
• Users' Guides to the Medical Literature: XIII. How to Use an Article on Economic Analysis of Clinical Practice A. Are the Results of the Study Valid?

  1997cited by this paper
• Positron emission tomography : descriptive analysis of experience with PET in VA : a systematic review update of FDG-PET as a diagnostic test in cancer and Alzheimer's disease

  1996cited by this paper
• Magnetic resonance coronary angiography--assessing an emerging technology.

  1993cited by this paper
• The Efficacy of Diagnostic Imaging

  1991cited by this paper
• Stage IV non-small-cell lung cancer: the guides are perplexed.

  1989cited by this paper
• Evaluating and comparing imaging techniques: a review and classification of study designs.

  1987cited by this paper
• The role of before-after studies of therapeutic impact in the evaluation of diagnostic technologies.

  1986cited by this paper
• The use of different induction and maintenance chemotherapy regimens for the treatment of advanced yolk sac tumors.

  1983cited by this paper
• Evaluation of computed tomography: achievement and challenge.

  1978cited by this paper
• Clinical efficacy of computed body tomography, II.

  1978cited by this paper
• Successful Immunizing Against Cancer1

  1923cited by this paper

• Assessment of PET imaging devices: the case of a LSO/NaI PET-SPECT prototype

  2007cites this paper